Treatment Strategies and Survival Outcomes in Breast Cancer
Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy, chemotherapy, and t...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Online |
| Kieli: | englanti |
| Julkaistu: |
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Aiheet: | |
| Linkit: | 46062 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|
| _version_ | 1869527245154942976 |
|---|---|
| author | Cheung, Kwok-Leung |
| author_browse | Cheung, Kwok-Leung |
| author_facet | Cheung, Kwok-Leung |
| author_sort | Cheung, Kwok-Leung |
| collection | Directory of Open Access Books |
| description | Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy, chemotherapy, and targeted therapy). Advances in technologies such as oncoplastic surgery, radiation planning and delivery, and genomics, and the development of novel systemic therapy agents alongside their evaluation in ongoing clinical trials continue to strive for improvements in outcomes. In this Special Issue, we publish a collection of studies looking at all forms of therapeutic strategies for early and advanced breast cancer, focusing on their outcomes, notably survival. |
| format | Online |
| id | doab-20.500.12854ir-61309 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-613092024-03-31T13:09:52Z Treatment Strategies and Survival Outcomes in Breast Cancer Cheung, Kwok-Leung R5-920 RC31-1245 relative survival young women cancer treatment n/a fulvestrant lapatinib tumor biology antihormone therapy mastectomy aromatase inhibitors chemotherapy serum biomarker cyclin E anthracycline resistance zero-inflated Poisson regression model lymph-node ratio CHEK2 comparative effectiveness breast-conserving therapy taxane sensitivity liquid biopsy HER2 c-erbB2 colorectal cancer infiltrating breast cancer survival exercise characteristics lactate dehydrogenase biomarker breast cancer survivors BRCA disease-free survival PIK3CA metastatic breast cancer cell-free DNA invasive breast cancer radiotherapy Metformin social well-being gene expression contralateral breast cancer basal-like breast cancer LMK-235 Src kinase HER2/neu LKB1 Older women LDH mutation carriers stage IV mammography screening NCDB cMet SEER pertuzumab physical function outcome ribociclib older patients geriatric oncology metastatic overdiagnosis next-generation sequencing abemaciclib Endocrine therapy monitoring metastatic breast cancer breast cancer circulating tumor cells Breast Cancer PALB2 histone deacetylase prognosis physical activity trastuzumab ductal carcinoma in situ contralateral prophylactic mastectomy ERCC1 family history T-DM1 ATM advanced breast cancer incidence palbociclib HDAC5 inhibitors APOBEC3B thema EDItEUR::M Medicine and Nursing Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy, chemotherapy, and targeted therapy). Advances in technologies such as oncoplastic surgery, radiation planning and delivery, and genomics, and the development of novel systemic therapy agents alongside their evaluation in ongoing clinical trials continue to strive for improvements in outcomes. In this Special Issue, we publish a collection of studies looking at all forms of therapeutic strategies for early and advanced breast cancer, focusing on their outcomes, notably survival. 2021-02-12T06:33:30Z 2021-02-12T06:33:30Z 2020-06-09 16:38:57 2020 book 46062 9783039287598 9783039287581 https://directory.doabooks.org/handle/20.500.12854/61309 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/2255 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03928-759-8 10.3390/books978-3-03928-759-8 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039287598 9783039287581 264 open access |
| spellingShingle | R5-920 RC31-1245 relative survival young women cancer treatment n/a fulvestrant lapatinib tumor biology antihormone therapy mastectomy aromatase inhibitors chemotherapy serum biomarker cyclin E anthracycline resistance zero-inflated Poisson regression model lymph-node ratio CHEK2 comparative effectiveness breast-conserving therapy taxane sensitivity liquid biopsy HER2 c-erbB2 colorectal cancer infiltrating breast cancer survival exercise characteristics lactate dehydrogenase biomarker breast cancer survivors BRCA disease-free survival PIK3CA metastatic breast cancer cell-free DNA invasive breast cancer radiotherapy Metformin social well-being gene expression contralateral breast cancer basal-like breast cancer LMK-235 Src kinase HER2/neu LKB1 Older women LDH mutation carriers stage IV mammography screening NCDB cMet SEER pertuzumab physical function outcome ribociclib older patients geriatric oncology metastatic overdiagnosis next-generation sequencing abemaciclib Endocrine therapy monitoring metastatic breast cancer breast cancer circulating tumor cells Breast Cancer PALB2 histone deacetylase prognosis physical activity trastuzumab ductal carcinoma in situ contralateral prophylactic mastectomy ERCC1 family history T-DM1 ATM advanced breast cancer incidence palbociclib HDAC5 inhibitors APOBEC3B thema EDItEUR::M Medicine and Nursing Cheung, Kwok-Leung Treatment Strategies and Survival Outcomes in Breast Cancer |
| title | Treatment Strategies and Survival Outcomes in Breast Cancer |
| title_full | Treatment Strategies and Survival Outcomes in Breast Cancer |
| title_fullStr | Treatment Strategies and Survival Outcomes in Breast Cancer |
| title_full_unstemmed | Treatment Strategies and Survival Outcomes in Breast Cancer |
| title_short | Treatment Strategies and Survival Outcomes in Breast Cancer |
| title_sort | treatment strategies and survival outcomes in breast cancer |
| topic | R5-920 RC31-1245 relative survival young women cancer treatment n/a fulvestrant lapatinib tumor biology antihormone therapy mastectomy aromatase inhibitors chemotherapy serum biomarker cyclin E anthracycline resistance zero-inflated Poisson regression model lymph-node ratio CHEK2 comparative effectiveness breast-conserving therapy taxane sensitivity liquid biopsy HER2 c-erbB2 colorectal cancer infiltrating breast cancer survival exercise characteristics lactate dehydrogenase biomarker breast cancer survivors BRCA disease-free survival PIK3CA metastatic breast cancer cell-free DNA invasive breast cancer radiotherapy Metformin social well-being gene expression contralateral breast cancer basal-like breast cancer LMK-235 Src kinase HER2/neu LKB1 Older women LDH mutation carriers stage IV mammography screening NCDB cMet SEER pertuzumab physical function outcome ribociclib older patients geriatric oncology metastatic overdiagnosis next-generation sequencing abemaciclib Endocrine therapy monitoring metastatic breast cancer breast cancer circulating tumor cells Breast Cancer PALB2 histone deacetylase prognosis physical activity trastuzumab ductal carcinoma in situ contralateral prophylactic mastectomy ERCC1 family history T-DM1 ATM advanced breast cancer incidence palbociclib HDAC5 inhibitors APOBEC3B thema EDItEUR::M Medicine and Nursing |
| topic_facet | R5-920 RC31-1245 relative survival young women cancer treatment n/a fulvestrant lapatinib tumor biology antihormone therapy mastectomy aromatase inhibitors chemotherapy serum biomarker cyclin E anthracycline resistance zero-inflated Poisson regression model lymph-node ratio CHEK2 comparative effectiveness breast-conserving therapy taxane sensitivity liquid biopsy HER2 c-erbB2 colorectal cancer infiltrating breast cancer survival exercise characteristics lactate dehydrogenase biomarker breast cancer survivors BRCA disease-free survival PIK3CA metastatic breast cancer cell-free DNA invasive breast cancer radiotherapy Metformin social well-being gene expression contralateral breast cancer basal-like breast cancer LMK-235 Src kinase HER2/neu LKB1 Older women LDH mutation carriers stage IV mammography screening NCDB cMet SEER pertuzumab physical function outcome ribociclib older patients geriatric oncology metastatic overdiagnosis next-generation sequencing abemaciclib Endocrine therapy monitoring metastatic breast cancer breast cancer circulating tumor cells Breast Cancer PALB2 histone deacetylase prognosis physical activity trastuzumab ductal carcinoma in situ contralateral prophylactic mastectomy ERCC1 family history T-DM1 ATM advanced breast cancer incidence palbociclib HDAC5 inhibitors APOBEC3B thema EDItEUR::M Medicine and Nursing |
| url | 46062 |
| work_keys_str_mv | AT cheungkwokleung treatmentstrategiesandsurvivaloutcomesinbreastcancer |